Predictors of Family Medicine Patient Retention in Opioid Medication-Assisted Treatment

References

1. 1.↵
   1. McLellan AT,
   2. Lewis DC,
   3. O’Brien CP,
   4. Kleber HD

   . Drug dependence, a chronic medical illness implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689–95.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Mintzer IL,
   2. Eisenberg M,
   3. Terra M,
   4. MacVane C,
   5. Himmelstein DU,
   6. Woolhandler S

   . Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007;5:146–50.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Martin SA,
   2. Chiodo LM,
   3. Wilson A

   . Retention in care as a quality measure for opioid use disorder. Subst Abus 2019;40:453–8.

   OpenUrl
4. 4.↵
   1. Timko C,
   2. Schultz NR,
   3. Cucciare MA,
   4. Vittorio L,
   5. Garrison-Diehn C

   . Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis 2016;35:22–35.

   OpenUrl
5. 5.↵
   1. Morgan JR,
   2. Schackman BR,
   3. Leff JA,
   4. Linas BP,
   5. Walley AY

   . Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat 2018;85:90–6.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Williams AR,
   2. Nunes EV,
   3. Bisaga A,
   4. et al

   . Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat 2018;91:57–68.

   OpenUrl
7. 7.↵
   1. Manhapra A,
   2. Petrakis I,
   3. Rosenheck R

   . Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. Am J Addict 2017;26:572–80.

   OpenUrl
8. 8.↵
   1. Damian AJ,
   2. Mendelson T,
   3. Agus D

   . Predictors of buprenorphine treatment success of opioid dependence in two Baltimore City grassroots recovery programs. Addict Behav 2017;73:129–32.

   OpenUrl
9. 9.↵
   1. Hser YI,
   2. Saxon AJ,
   3. Huang D,
   4. et al

   . Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014;109:79–87.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Marcovitz DE,
    2. McHugh RK,
    3. Volpe J,
    4. Votaw V,
    5. Connery HS

    . Predictors of early dropout in outpatient buprenorphine/naloxone treatment. Am J Addict 2016;25:472–7.

    OpenUrl
11. 11.↵
    1. Schuman-Olivier Z,
    2. Weiss RD,
    3. Hoeppner BB,
    4. Borodovsky J,
    5. Albanese MJ

    . Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat 2014;47:202–12.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Weinstein ZM,
    2. Kim HW,
    3. Cheng DM,
    4. et al

    . Long-term retention in office based opioid treatment with buprenorphine. J Subst Abuse Treat 2017;74:65–70.

    OpenUrlPubMed
13. 13.↵
    1. Neumann AM,
    2. Blondell RD,
    3. Azadfard M,
    4. Nathan G,
    5. Homish GG

    . Primary care patient characteristics associated with completion of 6-month buprenorphine treatment. Addict Behav 2013;38:2724–8.

    OpenUrl
14. 14.↵
    1. Brorson HH,
    2. Ajo Arnevik E,
    3. Rand-Hendriksen K,
    4. Duckert F

    . Drop-out from addiction treatment: A systematic review of risk factors. Clin Psychol Rev 2013;33:1010–24.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Armenian SH,
    2. Chutuape MA,
    3. Stitzer ML

    . Predictors of discharges against medical advice from a short-term hospital detoxification unit. Drug Alcohol Depend 1999;56:1–8.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Ejlertsson G,
    2. Berg S

    . Continuity-of-care measures: an analytic and empirical comparison. Med Care 1984;22:231–9.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Saultz JW

    . Defining and measuring interpersonal continuity of care. Ann Fam Med 2003;1:134–43.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Tousignant P,
    2. Diop M,
    3. Fournier M,
    4. et al

    . Validation of 2 new measures of continuity of care based on year-to-year follow-up with known providers of health care. Ann Fam Med 2014;12:559–67.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Carroll KM,
    2. Weiss RD

    . The role of behavioral interventions in buprenorphine maintenance treatment: A review. Am J Psychiatry 2017;174:738–47.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Fiellin DA,
    2. Barry DT,
    3. Sullivan LE,
    4. et al

    . A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med 2013;126:74.e11–7.

    OpenUrl
21. 21.↵
    1. Moore BA,
    2. Barry DT,
    3. Sullivan LE,
    4. et al

    . Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study. J Addict Med 2012;6:205–11.

    OpenUrlPubMed
22. 22.↵
    1. Weiss RD,
    2. Potter JS,
    3. Fiellin DA,
    4. et al

    . Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68:1238–46.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Fox AD,
    2. Masyukova M,
    3. Cunningham CO

    . Optimizing psychosocial support during office-based buprenorphine treatment in primary care: patients’ experiences and preferences. Subst Abus 2016;37:70–5.

    OpenUrl
24. 24.↵
    1. Parchman ML,
    2. Pugh JA,
    3. Hitchcock Noël P,
    4. Larme AC

    . Continuity of care, self-management behaviors, and glucose control in patients with type 2 diabetes. Med Care 2002;40:137–44.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Jeffers H,
    2. Baker M

    . Continuity of care: Still important in modern-day general practice. Br J Gen Pract 2016;66:396–7.

    OpenUrlFREE Full Text
26. 26.↵
    1. Tammes P,
    2. Salisbury C

    . Continuity of primary care matters and should be protected. BMJ 2017;356:j373.

    OpenUrlFREE Full Text
27. 27.↵
    1. Van Walraven C,
    2. Oake N,
    3. Jennings A,
    4. Forster AJ

    . The association between continuity of care and outcomes: a systematic and critical review. J Eval Clin Pract 2010;16:947–56.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Saultz JW,
    2. Lochner J

    . Interpersonal continuity of care and care outcomes: a critical review. Ann Fam Med 2005;3:159–66.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Fareed A,
    2. Eilender P,
    3. Ketchen B,
    4. et al

    . Factors affecting noncompliance with buprenorphine maintenance treatment. J Addict Med 2014;8:345–50.

    OpenUrl
30. 30.↵
    1. Barry DT,
    2. Irwin KS,
    3. Jones ES,
    4. et al

    . Integrating buprenorphine treatment into office-based practice: A qualitative study. J Gen Intern Med 2009;24:218–25.

    OpenUrlCrossRefPubMedWeb of Science